Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (204)	11/5/1998 12:20:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1073

"Bounce"....... DEPO bid has been at 1 31/32 for at least 20 minutes. 5,000 share sold, awaiting word from Jim S. regarding the remaining shares. nice call, Jim! SCIO hits $7 and is still moving. Big news, NRGN, up 15%.

To: jayhawk969 who wrote (204)	11/5/1998 2:23:00 PM
From: Russian Bear	Read Replies (2) \| Respond to of 1073

J.D., I believe that ONTAK is a combination Interleukin-2/diphtheria toxin protein, not a living bacteria. That would put it in a somewhat related, but distinct, category of agents. The elegant aspect of the purely bacteriological approaches of Drs. Rouslahti, Bermudez, etc., as I understand them, is that they propose to use perfectly virulent (albeit genetically altered) micro-organisms to infect tumor cells preferentially. OXGN's anaerobic bacteria approach is closely related, only requiring the further condition that tumors be thoroughly de-vascularized. ONTAK has the considerable virtue of being a much more mature agent, on the verge of almost certain FDA approval, but it is still, at bottom, a chemotherapeutic agent, albeit a well-targeted one. Regards, RB